PE20020866A1 - Metodos para tratar las enfermedades proliferativas - Google Patents

Metodos para tratar las enfermedades proliferativas

Info

Publication number
PE20020866A1
PE20020866A1 PE2002000087A PE2002000087A PE20020866A1 PE 20020866 A1 PE20020866 A1 PE 20020866A1 PE 2002000087 A PE2002000087 A PE 2002000087A PE 2002000087 A PE2002000087 A PE 2002000087A PE 20020866 A1 PE20020866 A1 PE 20020866A1
Authority
PE
Peru
Prior art keywords
cardiac
combination
tamoxyphene
hydrogenic
fludarabin
Prior art date
Application number
PE2002000087A
Other languages
English (en)
Spanish (es)
Inventor
David J Emanuel
Craig L Tendler
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20020866A1 publication Critical patent/PE20020866A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
PE2002000087A 2001-02-09 2002-02-07 Metodos para tratar las enfermedades proliferativas PE20020866A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26780701P 2001-02-09 2001-02-09

Publications (1)

Publication Number Publication Date
PE20020866A1 true PE20020866A1 (es) 2002-09-26

Family

ID=23020199

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000087A PE20020866A1 (es) 2001-02-09 2002-02-07 Metodos para tratar las enfermedades proliferativas

Country Status (7)

Country Link
US (1) US20020151508A1 (https=)
EP (1) EP1359942A1 (https=)
JP (1) JP2004518717A (https=)
CA (1) CA2437768A1 (https=)
MX (1) MXPA03007124A (https=)
PE (1) PE20020866A1 (https=)
WO (1) WO2002064168A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368013B (es) * 2001-02-19 2019-09-13 Novartis Ag Tratamiento de cáncer.
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
PL378812A1 (pl) * 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
CA2528545C (en) * 2003-06-13 2014-08-12 John Claude Savoir Process for the manufacture of stable shaped particles consisting of estradiol and cholesterol
CA2581133A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
KR100684380B1 (ko) 2005-05-24 2007-02-20 한국화학연구원 빗살형 폴리에틸렌글리콜을 결합한 리포솜 및 이의 제조방법
JP5333970B2 (ja) * 2007-03-20 2013-11-06 国立大学法人大阪大学 心筋梗塞の予防および／または治療薬
WO2014089127A1 (en) * 2012-12-03 2014-06-12 Merrimack Pharmaceuticals, Inc. Combination therapy for treating her2-positive cancers
SG11201509043RA (en) * 2013-05-14 2015-12-30 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
PL3055332T3 (pl) * 2013-10-08 2020-02-28 Immunogen, Inc. Schematy dawkowania immunokoniugatu anty-FOLR1
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
WO2000035455A1 (en) * 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
CZ20014083A3 (cs) * 1999-05-14 2002-08-14 Imclone Systems Incorporated Léčivo pro indikaci růstu refrakterních nádorů

Also Published As

Publication number Publication date
CA2437768A1 (en) 2002-08-22
EP1359942A1 (en) 2003-11-12
MXPA03007124A (es) 2003-11-18
US20020151508A1 (en) 2002-10-17
WO2002064168A1 (en) 2002-08-22
JP2004518717A (ja) 2004-06-24

Similar Documents

Publication Publication Date Title
PE20020866A1 (es) Metodos para tratar las enfermedades proliferativas
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
JO2503B1 (en) Benzathiazole derivatives
MEP13408A (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
PL1678166T3 (pl) Inhibitory kinaz białkowych
MXPA05010293A (es) 4-amino[1,2,4]triazolo[4,3-a]quinoxalinas sustituidas.
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX2009010378A (es) Metodos para tratar o prevenir el vomito utilizando secretagogos de hormona de crecimiento.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
NO20022065L (no) Terapeutisk anvendelse
CY1113138T1 (el) Παραγωγα 10,10-διαλκυλ προστανοϊκου οξεος ως παραγοντες για μειωση ενδο-οφθαλμικης πιεσης
GB0112348D0 (en) Compounds
EA200300266A1 (ru) Новые сложные эфиры апорфина и их применение в терапии
MX2007013624A (es) Inhibidores de proteina cinasa.
CO2023005979A2 (es) Conjugado anticuerpo-fármaco y aplicación del mismo
EE200000472A (et) Kasvajavastased toimeained
BR0115036A (pt) Processo para a preparação de um composto
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
MX2023009166A (es) Derivados de quinoxalina y sus usos.
CO2024012427A2 (es) Pirimidinas para degradar la tirosina quinasa de bruton
BRPI0713333A2 (pt) Potencializador de terapia de radiação
TR200102334T2 (tr) Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.
MX2023009962A (es) Composicion farmaceutica combinada que contiene inhibidor de cdk4/6 y su uso.
MX2009006634A (es) Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.

Legal Events

Date Code Title Description
FC Refusal